Onabotulinumtoxin A for the management of chronic migraine in current clinical practice: results of a survey of sixty-three Italian headache centers

Overview of attention for article published in The Journal of Headache and Pain, June 2017

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Good Attention Score compared to outputs of the same age (74th percentile)
Good Attention Score compared to outputs of the same age and source (66th percentile)

Mentioned by

policy: 1 policy source
twitter: 6 X users

facebook: 1 Facebook page

Citations

dimensions_citation: 27 Dimensions

Readers on

mendeley: 36 Mendeley

Summary Policy documents X Facebook Dimensions citations

So far, Altmetric has seen 1 policy document that references this research output.

Botulinum Toxin A for Chronic Migraines: Clinical Effectiveness

Cited by Canadian Agency for Drugs and Technologies in Health on 03 Jan 2018

CADTH is an independent, not-for-profit organization responsible for providing health care decision-makers with objective evidence to help make informed decisions about the optimal use of health technologies.

This page shows the most recent policy documents that mention this research output.

Click here to find out how to access more activity.